Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co. Ltd.) announced on June 19, 2024 that its subsidiary, Fosun Pharma Singapore, sold 9,900,000 shares of Gland Pharma Limited it held in a bulk transaction, accounting for approximately 6.01% of Gland Pharma's total shares, for a total consideration of INR 17.541 billion (approximately USD 211 million, pre-tax). The transaction price per share was discounted by about 3.69% compared to the closing price of Gland Pharma's previous trading day. After the transaction, Fosun Pharma's shareholding in Gland Pharma reduced from 57.84% to 51.83%, but still maintains controlling position. The proceeds from this transaction will be used to replenish the group's operating capital and repay interest-bearing debts, while increasing the group's net assets but will not be included in investment income. This transaction has been authorized by the 2022 shareholder's meeting and does not constitute a major asset reorganization.

Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co. Ltd.) announced on June 19, 2024 that its subsidiary, Fosun Pharma Singapore, sold 9,900,000 shares of Gland Pharma Limited it held in a bulk transaction, accounting for approximately 6.01% of Gland Pharma's total shares, for a total consideration of INR 17.541 billion (approximately USD 211 million, pre-tax). The transaction price per share was discounted by about 3.69% compared to the closing price of Gland Pharma's previous trading day. After the transaction, Fosun Pharma's shareholding in Gland Pharma reduced from 57.84% to 51.83%, but still maintains controlling position. The proceeds from this transaction will be used to replenish the group's operating capital and repay interest-bearing debts, while increasing the group's net assets but will not be included in investment income. This transaction has been authorized by the 2022 shareholder's meeting and does not constitute a major asset reorganization.